Cargando…
Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resista...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645714/ https://www.ncbi.nlm.nih.gov/pubmed/23574937 http://dx.doi.org/10.3390/ijms14047757 |
_version_ | 1782268529364434944 |
---|---|
author | Watahiki, Akira Macfarlane, Robyn J. Gleave, Martin E. Crea, Francesco Wang, Yuzhuo Helgason, Cheryl D. Chi, Kim N. |
author_facet | Watahiki, Akira Macfarlane, Robyn J. Gleave, Martin E. Crea, Francesco Wang, Yuzhuo Helgason, Cheryl D. Chi, Kim N. |
author_sort | Watahiki, Akira |
collection | PubMed |
description | MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resistant prostate cancer (mCRPC) from those with localized prostate cancer (PCa). Pooled plasma samples from patients with localized PCa or mCRPC (25 per group) were assayed using the Exiqon miRNA qPCR panel, and the differential expression of selected candidates was validated using qRT-PCR. We identified 63 miRNAs upregulated in mCRPC versus localized PCa, while only four were downregulated. Pearson’s correlation analysis revealed two highly correlated groups: one consisting of miR-141, miR375 and miR-200c and the other including miR151-3p, miR423-3p, miR-126, miR152 and miR-21. A third group, containing miR-16 and miR-205, showed less correlation. One miRNA from each group (miR-141, miR151-3p and miR-16) was used for logistic regression analysis and proved to increase the sensitivity of the prostate-specific antigen (PSA) test alone. While no miRNA alone differentiated localized PCa and mCRPC, combinations had greater sensitivity and specificity. The expression of these 10 candidates was assayed for association with clinical parameters of disease progression through the cBio portal. Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC. |
format | Online Article Text |
id | pubmed-3645714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-36457142013-05-13 Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer Watahiki, Akira Macfarlane, Robyn J. Gleave, Martin E. Crea, Francesco Wang, Yuzhuo Helgason, Cheryl D. Chi, Kim N. Int J Mol Sci Article MicroRNAs (miRNAs) have emerged as key regulators of numerous biological processes, and increasing evidence suggests that circulating miRNAs may be useful biomarkers of clinical disease. In this study, we sought to identify plasma miRNAs that differentiate patients with metastatic castration resistant prostate cancer (mCRPC) from those with localized prostate cancer (PCa). Pooled plasma samples from patients with localized PCa or mCRPC (25 per group) were assayed using the Exiqon miRNA qPCR panel, and the differential expression of selected candidates was validated using qRT-PCR. We identified 63 miRNAs upregulated in mCRPC versus localized PCa, while only four were downregulated. Pearson’s correlation analysis revealed two highly correlated groups: one consisting of miR-141, miR375 and miR-200c and the other including miR151-3p, miR423-3p, miR-126, miR152 and miR-21. A third group, containing miR-16 and miR-205, showed less correlation. One miRNA from each group (miR-141, miR151-3p and miR-16) was used for logistic regression analysis and proved to increase the sensitivity of the prostate-specific antigen (PSA) test alone. While no miRNA alone differentiated localized PCa and mCRPC, combinations had greater sensitivity and specificity. The expression of these 10 candidates was assayed for association with clinical parameters of disease progression through the cBio portal. Our results demonstrate that plasma levels of selected miRNAs are potential biomarkers to differentiate localized PCa and mCRPC. Molecular Diversity Preservation International (MDPI) 2013-04-10 /pmc/articles/PMC3645714/ /pubmed/23574937 http://dx.doi.org/10.3390/ijms14047757 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Watahiki, Akira Macfarlane, Robyn J. Gleave, Martin E. Crea, Francesco Wang, Yuzhuo Helgason, Cheryl D. Chi, Kim N. Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer |
title | Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer |
title_full | Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer |
title_fullStr | Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer |
title_full_unstemmed | Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer |
title_short | Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer |
title_sort | plasma mirnas as biomarkers to identify patients with castration-resistant metastatic prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645714/ https://www.ncbi.nlm.nih.gov/pubmed/23574937 http://dx.doi.org/10.3390/ijms14047757 |
work_keys_str_mv | AT watahikiakira plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer AT macfarlanerobynj plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer AT gleavemartine plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer AT creafrancesco plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer AT wangyuzhuo plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer AT helgasoncheryld plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer AT chikimn plasmamirnasasbiomarkerstoidentifypatientswithcastrationresistantmetastaticprostatecancer |